Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf.
- Published in:
- BioDrugs, 2017, v. 31, n. 6, p. 473, doi. 10.1007/s40259-017-0247-0
- By:
- Publication type:
- Article
Works matching IS 11738804 AND DT 2017 AND VI 31 AND IP 6
Results: 9
1
2
Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology.
- Published in:
- BioDrugs, 2017, v. 31, n. 6, p. 503, doi. 10.1007/s40259-017-0248-z
- By:
- Publication type:
- Article
3
Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants.
- Published in:
- BioDrugs, 2017, v. 31, n. 6, p. 545, doi. 10.1007/s40259-017-0249-y
- By:
- Publication type:
- Article
4
CGRP Monoclonal Antibodies for Migraine: Rationale and Progress.
- Published in:
- BioDrugs, 2017, v. 31, n. 6, p. 487, doi. 10.1007/s40259-017-0250-5
- By:
- Publication type:
- Article
5
The Application of CGRP(r) Monoclonal Antibodies in Migraine Spectrum: Needs and Priorities.
- Published in:
- BioDrugs, 2017, v. 31, n. 6, p. 483, doi. 10.1007/s40259-017-0251-4
- By:
- Publication type:
- Article
6
Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK.
- Published in:
- BioDrugs, 2017, v. 31, n. 6, p. 533, doi. 10.1007/s40259-017-0252-3
- By:
- Publication type:
- Article
7
ACKNOWLEDGEMENT TO REFEREES.
- Published in:
- BioDrugs, 2017, v. 31, n. 6, p. 469, doi. 10.1007/s40259-017-0253-2
- Publication type:
- Article
8
Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends.
- Published in:
- BioDrugs, 2017, v. 31, n. 6, p. 521, doi. 10.1007/s40259-017-0254-1
- By:
- Publication type:
- Article
9
GP2015: An Etanercept Biosimilar.
- Published in:
- BioDrugs, 2017, v. 31, n. 6, p. 555, doi. 10.1007/s40259-017-0246-1
- By:
- Publication type:
- Article